The Exchange had sought clarification from Nectar Lifesciences Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE had asked Nectar Lifesciences to explain why its financial results for the quarter ended 31-March-2025 were not submitted in the format prescribed by SEBI under Regulation 33 of the Listing Obligations and Disclosure Requirements. The company has now submitted its response to the exchange, which is enclosed with the filing. The original query was procedural in nature, related to the presentation format of the results rather than the numbers themselves. No details of the response contents have been disclosed in this announcement.
This is a routine procedural clarification on the format of already-submitted quarterly results and is unlikely to have any material impact on the stock price or shareholders. Investors should watch for any follow-up action from the exchange if the response is not found satisfactory.